RECOMENDAÇÕES PARA TERAPIA ANTI-RETROVIRAL EM ADULTOS INFECTADOS PELO HIV

RA. Co-infecção HIV-HCV como fator determinante 
da morbi-mortalidade de infecção pelo HIV e das respos-
tas imunológicas e virológicas à terapia anti-retroviral e 
de alta potência. Tese de doutorado. Medicina Tropical, 
Universidade Federal de Minas Gerais; 2003.
7. Pavan MH, Viral hepatitis in patients infected with immuno-
deficiency virus. Braz J Infect Dis 2003; 7 (4): 253-61.
8. Monteiro M R C C et al. Hepatite C: prevalência e fatores 
de risco entre portadores do VIH/SIDA em Belém, Pará, 
na Amazônia brasileira. Rev Soc Bras Med Tropical 2004; 
37 (SII) 40-46.
9. Segurado A C et al. Hepatitis C virus coinfection in a cohort 
of HIV-infected individuals from Santos, Brazil: seropre-
valence and associated factors. AIDS Patient Care STDS 
2004; 18 (3): 135-43.
10. Pio Marins, R et al Characteristic and survival of aids patients 
with hepatitis C: the Brazilian National Cohort of 1995 
– 1996. AIDS 2005; 19 (S4): S27-S30.
11. Pereira GA, Stefani MM, Martelli CM, Turcgi MD, Siqueira 
EM, Carneiro MA, Martins RM. Human immunodeficiency 
virus type 1 and hepatitis virus co-infection and viral sub-
types at an HIV testing center in Brazil. J Med Virol 2006; 
78 (6): 719-23.
12. Mendes-Corrêa, Risk factors associated with hepatitis C 
among HIV co-infected patients. a case-control study. Am 
J Trop Med and Hyg 2005; 72 (6), 762-7.
13. Rodrigues, SMC. Co-infecção HIV HCV em pacientes de 
Botucatu, Dissertação de mestrado, Faculdade de Medicina 
de Botucatu, 2005.
14. Brasil, Ministério da Saúde, Programa Nacional de DST/Aids, 
Boletim Epidemiológico – Aids e DST, ano IV n°1, 2007.
15. Graham CS, Baden LR, Yu E, et al. Influence of human im-
munodeficiency virus infection on the course of hepatitis 
C virus infection: a meta-analysis. Clinical Infect Dis 2002; 
2002, 100 (5): 1584-8. 
16. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. 
Hepatotoxicity associated with antiretroviral therapy in 
adults infected with human immunodeficiency virus and 
the role of hepatitis C or B virus infection. JAMA 2000; 
238 (1):74-80
17. Monteiro M R C C et al. Estudo Soroepidemiológico do 
vírus da Hepatite B entre portadores da imunodeficiência 
humana/SIDA na Cidade de Belém, Pará – Brasil. Revista 
da Sociedade Brasileira de Medicina Tropical 2004; 37 (S 
II) 27-32. 
18. Pio Marins R. Estudo de sobrevida dos pacientes com Aids 
segundo escolaridade e co-infecção por Hepatite C e Tuber-
culose. Coorte Brasileira de 1995-96. Tese de Doutorado, 
Faculdade de Ciências Médicas da Universidade Estadual 
de Campinas UNICAMP, áreas de concentração em Saúde 
Coletiva, 2004.
19. Niel C, Moraes MT, Gaspar AM, Yoshida CF, Gomes SA. 
Genetic diversity of hepatitis B virus strains isolated in Rio 
de Janeiro, Brazil. J Med Virol 1994;44(2):180-6.
20. LAi, C; Ratziu V; Yen MF, Poynard T. Viral hepatitis B. Lancet; 
362 (9401): 2089-94, 2003.
21. Bodsworth NJ, Cooper D, Donovan B. The influence of 
human immunodeficiency virus type 1 infection on the 
development of the hepatitis B virus carrier state. J Infect 
Dis 1991; 163:1138-40
22. Housset C, Pol S, Carnot F, Dubois F, Nalpas B, Housset 
B, et al. Interactions between human immunodeficiency 
virus-1, hepatitis deltavirus and hepatitis B virus infections 
in 260 chronic carriers of hepatitis B virus. Hepatology 
1992;15:578-583.
23. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz 
A, et al. HIV-1, hepatitis B virus, and risk of liver-related 
mortality in the Multicenter Cohort Study (MACS). Lancet 
2002; 360:1921-1926
24. Bodsworth NJ, Cooper D, Donovan B. The influence of 
human immunodeficiency virus type 1 infection on the 
development of the hepatitis B virus carrier state. J Infect 
Dis 1991; 163:1138–40.
25. Lascar RM, Lopes AR, Gilson RJ, et all. Effect of HIV infection 
and antiretroviral therapy on hepatitis B virus (HBV)-spe-
cific T cell responses in patients who have resolved HBV 
infection. J Infect Dis 2005. 191 (7)1169-79.
26. Hofer, M Joller-Jemelka H; Grob P; Luthy R; Opravil M. Fre-
Guia de Tratamento100
quent chronic hepatitis B virus infection in HIV- infected 
patients positive for antibody to hepatitis B core antigen 
only. Swiss HIV cohort study. Eur J Clin Microbiol Infect 
Dis 1998, 17: 6-13. 
27. Neau D; Winnock M; Jouncencel A-C et al. Occult hepatitis 
B virus infection in HIV-infected patients with isolated 
antibodies to hepatitis B core antigen: Acquitane cohort, 
2002-2203. Clin Infect Dis 2005; 40:750-3.
28. Miailhes P, Trabaud MA, Pradat P, et al. Impact of highly 
active antiretroviral therapy (HAART) on the natural history 
of hepatitis b virus (HBV) and HIV coinfection: relationship 
between prolonged efficacy of HAART and HBV surface 
and early antigen seroconversion. Clin Infect Dis 2007; 
45:624–32.
29. Ockenga J, Tillmann HL, Trautwein C, Stoll M, Manns 
MP, Schmidt RE. Hepatitis B and C in HIV-infected pa-
tients: prevalence and prognostic value. J Hepatol 1997; 
27:18–24.
30. Chung, R. Peginterferon alfa –2a plus ribavirin versus inter-
feron alfa-2a plus ribavirin for chronic hepatitits C in HIV-
coinfected person. The New England Journal of Medicine. 
2004; 351 (5): 451-459.
31. Perronne C et al. Final results of ANRS HC02-RIBAVIC: A 
Randomized Controlled Trial of Pegylated-Interferon-alfa-
2b plus Ribavirin vs Interferonalfa- 2b plus Ribavirin for the 
Initial Treatment of Chronic Hepatitis C in HIV Co-Infected 
Patients. Abstract 117LB. 11th Conference on Retroviruses 
and Opportunistic Infections. February 8–11, 2004. San 
Francisco, CA. 
32. Moreno L. Pegylated INF- alfa 2b plus Ribavirina as therapy 
for treatment of chronic hepatitis C in HIV infected patients, 
AIDS 2004; 18 (1):67-73.
33. Torriani F. Pegyinterferon alfa-2a plus Ribavirina versus 
interferon alfa -2a plus Ribavirina for chronic hepatitits C 
virus infection in HIV infected patients, The New England 
Journal Of Medicine 2004; 351(5):438-50.
34. Crespo, et al. Pegylated INF- alfa 2b plus Ribavirina vs al-
fainterferona alfa 2b plus ribavirina for chronic hepatitits C 
in HIV-coinfected. Journal Viral Hepatology 2006.
35. M Deutsch and SJ Hadziyannis. Old and emerging therapies 
in chronic hepatitis C: an update. Journal of Viral Hepatitis 
2008; 15: 2-15.
36. Brasil, Ministério da Saúde, Portaria nº. 34, de 28 de se-
tembro de 2007.
37. Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu 
G, et al. Short statement of the first European Consensus 
Conference on the treatment of chronic hepatitis B and C 
in HIV co-infected patients. J Hepatol 2005; 42:615-624.
38. Lok ASF; McMahon BJ. AASLD practices guidelines. Hepa-
tology 2007;45: 507-539.
39. Lai, C; Ratziu V; Yen MF, Poynard T. Viral hepatitis B. Lancet 
2003; 20. 362 (9401): 2089-94. 
40. Liaw YF. Impact of YMDD mutation during lamivudine 
therapy in patients with chronic hepatitis B. Antivr Chem 
Chemother 2001; 12 Suppl 1: 67-71.
41. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim 
SG, Dent JC, Edmundson S, Condreay LD, Chien RN. Asia 
Hepatis Lamivudine Study Group. Hepatology 2001; 33 
(6):1527-32. 
42. Chang TT; Lai CL; Chien RN, Guan R; Lim SG; Lee CM; Ng KY; 
Nicholls GJ; Dent JC; Leung, NW. Four Years of lamivudine 
treatment in Chinese patients with chronic hepatitis B. J 
Gastoenterol Hepatol 2004; 19 (11): 1276-82.
43. Benhamou Y; Bochet M; Thiabault V; Di Martino V; Caumes 
E; Bricaire F; Opolon P; Katiana C; Poynard T. Long- term 
incidence of hepatitis B virus resistance to maivucine in hu-
man immunodeficiency virus-infected patients. Hepatology 
1999; 30 (5): 1302-6.
Recomendações para Terapia Anti-retroviral em Adultos Infectados pelo HIV 101
CO-INFECÇÃO HIV/TB 
Epidemiologia
A convergência das epidemias de tuberculose e 
HIV é um dos maiores desafios para a saúde publica 
no mundo. De acordo com as estimativas da OMS, o 
Brasil tem 110.000 casos novos a cada ano, sendo o 
país com o maior